{"id":16177,"date":"2021-03-03T17:55:44","date_gmt":"2021-03-03T16:55:44","guid":{"rendered":"https:\/\/www.izb-online.de\/morphosys-erhaelt-16-millionen-euro-als-meilensteinzahlung-von-gsk\/"},"modified":"2021-03-03T18:02:55","modified_gmt":"2021-03-03T17:02:55","slug":"morphosys-erhaelt-16-millionen-euro-als-meilensteinzahlung-von-gsk","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/morphosys-receives-16-million-euros-as-milestone-payment-from-gsk\/","title":{"rendered":"MorphoSys receives 16 Million Euros as milestone payment from GSK"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

MorphoSys receives 16 Million Euros as milestone payment from GSK<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]MorphoSys AG, a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that its licensing partner GlaxoSmithKline plc reported preliminary results of the OSCAR (Otilimab\u202fin Severe COVID-19 Related Disease) study using otilimab (formerly MOR103\/GSK3196165) for the treatment of severe pulmonary COVID-19 related disease. Given these data suggest an important clinical benefit in a pre-defined sub-group of high-risk patients and the urgent public health need, GSK has amended the OSCAR study to expand this cohort to confirm these potentially significant findings. This event of the first patient dosed in the expanded study triggers milestone payments of a total of 16 million Euro to MorphoSys.[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]March 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”16168″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 MorphoSys AG[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]MorphoSys and GSK are collaborating to develop a drug to treat severe COVID-19 lung disease in patients over the age of 70[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cThe preliminary study results with otilimab are encouraging news for patients 70 and older with severe COVID-19 related pulmonary disease.\u201d<\/h6>\n

Dr. Malte Peters
\nChief Research and Development Officer, MorphoSys AG<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Otilimab is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that was generated by MorphoSys and outlicensed to GSK in 2013. GSK is also developing otilimab for the treatment of rheumatoid arthritis in the ongoing Phase 3 ContRAst trials.<\/p>\n

\u201cThe preliminary study results with otilimab are encouraging news for patients 70 and older with severe COVID-19 related pulmonary disease,\u201d said Dr. Malte Peters, Chief Research and Development Officer of MorphoSys AG. \u201cWe are pleased that our licensing partner GSK is expanding the study in order to further explore otilimab as a potential treatment option for this group of older adults suffering from severe forms of COVID-19.\u201d<\/p>\n

About the OSCAR study
\n<\/strong>This global, randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept phase 2a OSCAR study (NCT04376684) assessed the efficacy and safety of a single intravenous infusion of otilimab 90 mg given over an hour or placebo in addition to standard of care in 806 hospitalised adults (ages 18 to 79 years) with severe COVID-19 related pulmonary disease. Standard of care permitted the use of corticosteroids (including dexamethasone), remdesivir, and convalescent plasma according to local hospital\/institutional policies. Study participants were enrolled at 130 sites around the world, including in the United States, Europe, Asia, Russia, South Africa and South America. All participants had a positive SARS-CoV-2 test result; been hospitalised due to a diagnosis of pneumonia; had new onset of oxygenation impairment requiring high-flow oxygen, non-invasive ventilation or mechanical ventilation <48 hours before dosing; and had increased biological markers of systemic inflammation.<\/p>\n

Participants were considered \u201calive and free of respiratory failure\u201d if they were off significant oxygen support measured using a GlaxoSmithKline (GSK) modified version ordinal scale adapted from World Health Organization (WHO) scale 2020. A full analysis is ongoing and will be made available in an upcoming pre-print publication when available.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n \n
\n MorphoSys AG <\/div>\n\n